Differences in persistence among different weekly oral bisphosphonate medications

Osteoporosis International

Volumn 20, Issue 8, 2009, Pages 1369-1376

  Sheehy, O ^a   Kindundu, C M ^b   Barbeau, M ^b   Lelorier, J ^a,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Novartis Pharmaceuticals Canada   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adherence; Bisphosphonates; Compliance; Database; Generic; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GENERIC DRUG; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; DATA BASE; DRUG DOSAGE FORM COMPARISON; DRUG WITHDRAWAL; FEMALE; FRACTURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK FACTOR; SEX DIFFERENCE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUGS, GENERIC; EPIDEMIOLOGIC METHODS; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; LENGTH OF STAY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT ACCEPTANCE OF HEALTH CARE; QUEBEC; SEX FACTORS;

EID: 67650474773     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0795-8     Document Type: Article

References (38)

1. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy JAMA 285 785 795
2. SR Cummings LJ Melton 2002 Epidemiology and outcomes of osteoporotic fractures Lancet 359 1761 1767
3. MR McClung 2000 Bisphosphonates in osteoporosis: recent clinical experience Expert Opin Pharmacother 1 225 238
4. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino JA Rodriguez-Portales RW Downs J Gupta AC Santora UA Liberman 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199 (Pubitemid 38339363)
5. CH van den Boogaard NS Breekveldt-Postma SE Borggreve WG Goettsch RM Herings 2006 Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study Curr Med Res Opin 22 1757 1764 (Pubitemid 44449232)
6. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 (Pubitemid 41368578)
7. JS McCombs P Thiebaud C McLaughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 (Pubitemid 38781153)
8. FJ Penning-van Beest WG Goettsch JA Erkens RM Herings 2006 Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis Clin Ther 28 236 242 (Pubitemid 44287822)
9. P Sambrook 2006 Compliance with treatment in osteoporosis patients-an ongoing problem Aust Fam Physician 35 135 137
10. KE Ensrud EL Barrett-Connor A Schwartz AC Santora DC Bauer S Suryawanshi A Feldstein WL Haskell MC Hochberg JC Torner A Lombardi DM Black 2004 Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension J Bone Miner Res 19 1259 1269 (Pubitemid 41094366)
11. SJ Neele R Evertz G Valk-De Roo JC Roos JC Netelenbos 2002 Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women Bone 30 599 603 (Pubitemid 34270498)
12. RA Yood S Emani JI Reed BE Lewis M Charpentier E Lydick 2003 Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 965 968 (Pubitemid 40824268)
13. JJ Caro KJ Ishak KF Huybrechts G Raggio C Naujoks 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008 (Pubitemid 40064656)
14. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 (Pubitemid 44498580)
15. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 (Pubitemid 44175011)
16. DE Baker 2002 Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity Rev Gastroenterol Disord 2 20 33 (Pubitemid 34467666)
17. R Tamblyn G Lavoie L Petrella J Monette 1995 The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec J Clin Epidemiol 48 999 1009
18. R Tamblyn T Reid N Mayo P McLeod M Churchill-Smith 2000 Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment J Clin Epidemiol 53 183 194 (Pubitemid 30151224)
19. E Garbe J Lelorier JF Boivin S Suissa 1997 Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids Lancet 350 979 982 (Pubitemid 27421106)
20. D Pilon AM Castilloux M Dorais J Lelorier 2004 Oral anticoagulants and the risk of osteoporotic fractures among elderly Pharmacoepidemiol Drug Saf 13 289 294 (Pubitemid 38697049)
21. C Quach JP Collet J Lelorier 2005 Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study Pharmacoepidemiol Drug Saf 14 163 170 (Pubitemid 40360769)
22. E Rahme MA Marentette SX Kong J Lelorier 2002 Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population Arthritis Rheum 47 595 602 (Pubitemid 35461311)
23. E Rahme D Pettitt J Lelorier 2002 Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population Arthritis Rheum 46 3046 3054 (Pubitemid 35315900)
24. E Rahme DJ Watson SX Kong Y Toubouti J Lelorier 2007 Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study Pharmacoepidemiol Drug Saf 16 493 503 (Pubitemid 46824270)
25. A Rakel O Sheehy E Rahme J Lelorier 2007 Does diabetes increase the risk for fractures after solid organ transplantation? A nested case-control study J Bone Miner Res 22 12 1878 1884 (Pubitemid 351229304)
26. M Von Korff EH Wagner K Saunders 1992 A chronic disease score from automated pharmacy data J Clin Epidemiol 45 197 203
27. J Blouin A Dragomir LG Ste-Marie JC Fernandes S Perreault 2007 Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women J Clin Endocrinol Metab 92 887 894 (Pubitemid 46465659)
28. JA Cramer NO Lynch AF Gaudin M Walker W Cowell 2006 The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France Clin Ther 28 1686 1694 (Pubitemid 44838898)
29. KE Hansen ED Swenson B Baltz AA Schuna AN Jones ME Elliott 2007 Adherence to alendronate in male veterans Osteoporos Int 19 3 349 356 (Pubitemid 351199186)
30. S Perreault A Dragomir L Blais Y Moride M Rossignol LG Ste-Marie JC Fernandes 2008 Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture Pharmacoepidemiol Drug Saf 17 3 248 259
31. AD Anastasilakis DG Goulis M Kita A Avramidis 2007 Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases Hormones (Athens ) 6 233 241
32. M Rossini G Bianchi O Di Munno S Giannini S Minisola L Sinigaglia S Adami 2006 Determinants of adherence to osteoporosis treatment in clinical practice Osteoporos Int 17 914 921 (Pubitemid 43781506)
33. W Strampel R Emkey R Civitelli 2007 Safety considerations with bisphosphonates for the treatment of osteoporosis Drug Saf 30 755 763 (Pubitemid 47351214)
34. C Turbi G Herrero-Beaumont JC Acebes A Torrijos J Grana R Miguelez J Sacristan F Marin 2004 Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study Clin Ther 26 245 256 (Pubitemid 38339016)
35. M Shakweh I Bravo-Osuna G Ponchel 2007 Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate Eur J Pharm Sci 31 262 270 (Pubitemid 47068937)
36. S Epstein B Cryer S Ragi JR Zanchetta J Walliser J Chow MA Johnson AE Leyes 2003 Disintegration/dissolution profiles of copies of Fosamax (alendronate) Curr Med Res Opin 19 781 789 (Pubitemid 37466149)
37. EJ Roldan O Quattrocchi D Zanetti E Piccinni J Tessler LE Caballero AP Lloret 2005 In vitro and in vivo equivalence studies of alendronate monosodium tablets Arzneimittelforschung 55 93 101 (Pubitemid 40327383)
38. DT Grima A Papaioannou MF Thompson MK Pasquale JD Adachi 2007 Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis Osteoporos Int 19 5 687 697